

# Discussion: Sildenafil case

C. Male, Paediatric Committee

- Similarity of disease?
- Similarity of response to treatment?
  - Pathophysiology; pharmacology
  - Historical data
  - Evolving data

# Discussion: Sildenafil case

## Pharmakokinetics:

- Could the initial dose-projection be improved
  - Physiology-based model
  - Separate PK study
  - Age-staggered approach
- Dosing by weight categories (8-20; 20-45; >45kg) rather than individual weight-adjusted dosing
  - high variability of actual doses and overlap between dose categories
  - Analysis by actual doses/exposures?
- Lack of age-appropriate formulation
- Age-groups ignored

# Discussion: Sildenafil case

## Endpoint correlations (translation):

Literature: 6MWT ~ morbidity & mortality (adults)

Literature: CPET ~ morbidity & mortality (adults)

Literature: 6MWT ~ CPET (some limitations) (adults and children)

FDA/Sildenafil: 6MWT ~ PVRI (adults)

Sildenafil: CPET ~ PVRI (children) ?

6MWT ~ PVRI<sub>adults</sub> = CPET ~ PVRI<sub>children</sub> ??

data in children unable for CPET ?

- Approach generally supported but not all assumptions validated
- Measure further endpoints in parallel (TTCW, echo, BNP, etc)
- Further validation across several trials/drugs